Clinical Trials Logo

Pancreatic Neuroendocrine Cancer clinical trials

View clinical trials related to Pancreatic Neuroendocrine Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02806648 Completed - Clinical trials for Pancreatic Neuroendocrine Cancer

A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)

PALBONET
Start date: May 2015
Phase: Phase 2
Study type: Interventional

A phase II trial to assess the activity and safety of PD0332991 in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET) with overexpression of cell cycle markers (Cdk4 and/or phospho-Rb1 and/or cyclin D1)

NCT ID: NCT01603004 Completed - Clinical trials for Pancreatic Neuroendocrine Cancer

Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors

Start date: May 14, 2012
Phase:
Study type: Observational

Sunitinib and everolimus are two new treatments approved in 2011 for patients with pancreatic neuroendocrine tumors (NETs). In addition, some traditional chemotherapies are often used to treat pancreatic NETs. Traditional chemotherapy is also known as "cytotoxic therapy" and works by killing cells that are actively dividing. There have been no studies to compare the different types of treatment. Since the patient is eligible for treatment with either sunitinib, everolimus or traditional chemotherapy it can help us identify factors that may help future patients benefit from these therapies.